Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus

被引:15
|
作者
Holmberg, Dag [1 ]
Ness-Jensen, Eivind [1 ]
Mattsson, Fredrik [1 ]
El-Serag, Hashem B. [2 ]
Lagergren, Jesper [1 ,3 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp, Dept Mol Med & Surg, Upper Gastrointestinal Surg, NS 67, S-17176 Stockholm, Sweden
[2] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA
[3] Kings Coll London, Div Canc Studies, Guys Campus, London SE1 1UL, England
基金
瑞典研究理事会;
关键词
Oesophageal adenocarcinoma; Oesophageal neoplasm; Surveillance; Barrett's oesophagus; High-grade dysplasia; LOW-GRADE DYSPLASIA; ENDOSCOPIC SURVEILLANCE; GENERAL-POPULATION; COST-EFFECTIVENESS; CANCER-RISK; METAANALYSIS; PROGRESSION; DIAGNOSIS; MORTALITY; SYMPTOMS;
D O I
10.1016/j.ejca.2016.12.037
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Recent studies have indicated a lower incidence rate of oesophageal adenocarcinoma (OAC) in individuals with Barrett's oesophagus (BO) than most earlier studies. Our objective was to assess the risk of OAC in a Swedish unselected cohort of individuals with BO. Methods: This population-based cohort study included all Swedish residents diagnosed with BO in 2006-2013, identified through the Swedish Patient Registry. The cohort members were followed from the date of first BO diagnosis until the first occurrence of OAC, high-grade dysplasia (HGD), death, emigration or end of study period. The main outcome was incidence rates with 95% confidence intervals (CIs) of OAC. Results: Among 7932 participants with BO and 18,415 person-years of follow-up, the overall incidence of OAC was 1.47 (95% CI 0.91-2.02) per 1000 person-years. When stratified into follow-up periods after BO diagnosis, the incidence rate of OAC was 15.53 (4.77-26.29) from 7 to 30 d, 4.10 (0.82-7.38) from 31 to 100 d, 1.87 (0.00-3.99) from 101 d to 6 months, 1.44 (0.18-2.70) from >6 months to 1 year, 0.94 (0.36-1.53) from >1 year to 3 years and 2.17 (1.14 3.21) from >3 years to the end of follow-up. The median follow-up time was 2.13 person-years. Conclusion: This population-based study indicates that OAC is primarily diagnosed during the first months following an initial diagnosis of BO. This could justify a changed surveillance strategy of BO with a repeated thorough endoscopy shortly after initial BO diagnosis to identify prevalent early OAC or HGD. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:41 / 46
页数:6
相关论文
共 50 条
  • [21] Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma:Results from the FINBAR study
    Lesley A Anderson
    RG Peter Watson
    Seamus J Murphy
    Brian T Johnston
    Harry Comber
    Jim Mc Guigan
    John V Reynolds
    Liam J Murray
    World Journal of Gastroenterology, 2007, (10) : 1585 - 1594
  • [22] LIFETIME RISK OF OESOPHAGEAL ADENOCARCINOMA IN PATIENTS WITH BARRETT'S COLUMNAR-LINED OESOPHAGUS REGISTERED WITH UK NATIONAL BARRETT'S OESOPHAGUS REGISTRY
    Gatenby, P.
    Caygill, C. P.
    Wall, C.
    Bhatacharjee, S.
    Ramus, J. R.
    Watson, A.
    Winslet, M. C.
    GUT, 2011, 60
  • [23] Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma
    Barclay, JY
    Morris, A
    Nwokolo, CU
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (02) : 221 - 227
  • [24] Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma
    Buas, Matthew F.
    He, Qianchuan
    Johnson, Lisa G.
    Onstad, Lynn
    Levine, David M.
    Thrift, Aaron P.
    Gharahkhani, Puya
    Palles, Claire
    Lagergren, Jesper
    Fitzgerald, Rebecca C.
    Ye, Weimin
    Caldas, Carlos
    Bird, Nigel C.
    Shaheen, Nicholas J.
    Bernstein, Leslie
    Gammon, Marilie D.
    Wu, Anna H.
    Hardie, Laura J.
    Pharoah, Paul D.
    Liu, Geoffrey
    Iyer, Prassad
    Corley, Douglas A.
    Risch, Harvey A.
    Chow, Wong-Ho
    Prenen, Hans
    Chegwidden, Laura
    Love, Sharon
    Attwood, Stephen
    Moayyedi, Paul
    MacDonald, David
    Harrison, Rebecca
    Watson, Peter
    Barr, Hugh
    deCaestecker, John
    Tomlinson, Ian
    Jankowski, Janusz
    Whiteman, David C.
    MacGregor, Stuart
    Vaughan, Thomas L.
    Madeleine, Margaret M.
    GUT, 2017, 66 (10) : 1739 - 1747
  • [25] Does a prior diagnosis of Barrett's oesophagus influence risk of dying from oesophageal adenocarcinoma?
    Whiteman, David C.
    GUT, 2015, 64 (01) : 5 - U248
  • [26] GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma
    Pavlov, Kirill
    Honing, Judith
    Meijer, Coby
    Boersma-van Ek, Wytske
    Peters, Frans T. M.
    van den Berg, Anke
    Karrenbeld, Arend
    Plukker, John T. M.
    Kruyt, Frank A. E.
    Kleibeuker, Jan H.
    DIGESTIVE AND LIVER DISEASE, 2015, 47 (01) : 73 - 80
  • [27] The role of DNA damage in the development of Barrett's oesophagus and oesophageal adenocarcinoma
    Olliver, JR
    Hardie, LJ
    Clark, GWB
    Dexter, S
    Chalmers, D
    Wild, CP
    BRITISH JOURNAL OF CANCER, 2002, 86 : S51 - S52
  • [28] Risk of Barrett's oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications
    Ladanchuk, Todd C.
    Johnston, Brian T.
    Murray, Liam J.
    Anderson, Lesley A.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2010, 45 (12) : 1397 - 1403
  • [29] Endoscopic Management of Dysplastic Barrett's Oesophagus and Early Oesophageal Adenocarcinoma
    Eusebi, Leonardo Henry
    Telese, Andrea
    Castellana, Chiara
    Engin, Rengin Melis
    Norton, Benjamin
    Papaefthymiou, Apostolis
    Zagari, Rocco Maurizio
    Haidry, Rehan
    CANCERS, 2023, 15 (19)
  • [30] Isothiocyanates inhibit proliferation of barrett's oesophagus and oesophageal adenocarcinoma cells
    Ogunwobi, O. O.
    Mutungi, G.
    Beales, I. L. P.
    GUT, 2008, 57 : A127 - A127